Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Cytori Provides Latest Corporate Update at Source Capital Conference

PSTV

Presentation on February 10, 2016 at 10:45 AM Eastern Time

Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that the company will present at the Source Capital 2016 Disruptive Growth & Healthcare Conference at 10:45 AM Eastern Time (7:45 AM Pacific Time) on Wednesday, February 10, 2016. The presentation will take place in the Tribeca Hub room at the Convene in New York City. For more information on the conference or for investors to register, please go to www.SourceCapitalConference.com.

Dr. Marc Hedrick, CEO and President of Cytori Therapeutics, will provide an update on current corporate activities and recent developments, including progress on the STAR trial, the U.S. phase III trial focused on Scleroderma related hand dysfunction, and other pipeline programs.

A live audio and video webcast of the presentation will be available under the investor relations section of Cytori’s website at www.cytori.com (http://ir.cytori.com). A replay of the presentation will be available for 90 days following the event. Please connect to Cytori’s website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Cytori Therapeutics

Cytori Therapeutics is a late stage cell therapy company developing autologous cell therapies from adipose tissue to treat a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products. For more information: visit www.cytori.com.

About Source Capital Group

Source Capital Group, Inc. was founded in 1992 on the belief that the best investment advice should be independent, unbiased and tailor-made for the individual client’s needs. Source Capital began as a boutique investment banking firm specializing in small to medium sized transactions. We have grown to include businesses in general securities, emerging market securities, distressed and high yield debt securities, in addition to our investment banking activity. http://www.sourcegrp.com/

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking statements that involve known and unknown risks and uncertainties. All statements, other than historical facts are forward-looking statements. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. These risks and uncertainties are described under the "Risk Factors" in Cytori's Securities and Exchange Commission Filings, included in our annual and quarterly reports.

There may be events in the future that we are unable to predict, or over which we have no control, and our business, financial condition, results of operations and prospects may change in the future. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless we have an obligation under U.S. Federal securities laws to do so.

Cytori Therapeutics, Inc.
Tiago Girao, +1 (858) 458.0900
ir@cytori.com



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today